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DRUG RESISTANCE ASSOCIATED PROPERTIES OF BLASTS 
SUBPOPULATIONS WITH DIFFERENT CD34 EXPRESSION 
IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
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Aim: The objective of this study was to investigate expression of drug resistance associated genes in CD34+ and CD34- leukemic 
subpopulations in childhood acute lymphoblastic leukemia (ALL). Methods: ALL samples with heterogeneous CD34 expression were 
separated into CD34-positive and CD34-negative subpopulations and mRNA levels of MDR1, LRP , BCRP and BCL-2 genes were 
compared. Results: BCL-2 gene expression levels did not differ significantly between CD34+ vs CD34− subpopulations in most 
analyzed ALL cases. Oppositely, MDR1 gene had >two-fold differences in expression levels between subpopulations in the major-
ity of ALL cases. In T-lineage ALL CD34− fractions had increased level of BCRP and LRP genes in comparison with CD34+ 
ones whereas in most of B-lineage ALL expression of these genes did not differ. Conclusion: It was not found the unique pattern 
of resistance related genes expression in CD34+ vs CD34− subpopulations. However, in majority of studied pediatric ALL cases 
with CD34 heterogeneous expression one of subpopulations (positive or negative) could have an advantage for survival through 
elevated expression of drug resistance related genes.
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In spite of substantial improvement in treatment 
of childhood acute leukemia that has been achieved 
during the past decades, a relapse still proves 
to be a major obstacle on the way to a prolonged 
complete remission [1]. Patients diagnosed with acute 
lymphoblastic leukemia (ALL) and receiving treatment 
in accordance with current protocols still face an ap-
proximately 20% chance of a relapse [2–5].
Minimal residual disease (MRD) monitoring 
provides important information for early prediction 
of a recurrence of the illness, however immunopheno-
typic modulation (shifts in immunophenotypic markers 
of leukemic cells during treatment and at relapse) and 
presence of several immunophenotypic subpopula-
tions provide additional difficulties for clinicians [6–7]. 
CD34 is a stage-specific antigen that is expressed 
on human hematopoietic stem and progenitor cells 
whose expression decreases with differentiation of the 
cell. CD34 marker is broadly used in ALL diagnostics 
and MRD monitoring [8–9]. However, it has been dem-
onstrated significant reduction of CD34 expression 
during induction therapy in childhood ALL [10]. Those 
phenotypic changes could be a result of drug exposure 
or caused by a clonal selection during chemotherapy.
In this study we tried to elucidate if immunopheno-
typically heterogeneous subpopulations of leukemic 
cells differed in expression of drug resistance related 
genes in childhood ALL. Previously, some properties 
of CD34+ vs CD34− leukemic subpopulations were in-
vestigated in acute myeloid leukemia (AML) samples. 
It was found that predominantly CD34+ fractions were 
more resistant to apoptosis, had increased expression 
levels of antiapoptotic and drug resistance associated 
genes/proteins compared to a corresponding CD34− 
one [11–13]. Although other authors stated that during 
chemotherapy CD34+ leukemic cells depleted more 
rapidly than CD34− cells [14]. Therefore, the absence 
of publications about “resistance associated” proper-
ties of CD34+/CD34− leukemic fractions in ALL provides 
an interesting field for investigations in this area.
With regard to the facts mentioned above we stud-
ied bone marrow samples taken at diagnosis of child-
hood T- and B-lineage ALL. For an in-depth study, all 
samples with heterogeneous CD34 expression were 
separated into CD34-positive and negative subpopula-
tions and mRNA levels of multidrug resistance genes, 
antiapoptotic gene BCL-2 were compared.
MATERIALS AND METHODS
Patients. 17 children at the median age of 10 years 
(range, 1–18) with ALL were taken in this study. 11 pa-
tients were diagnosed as pro-B, common or pre-B ALL 
(B-cell precursor ALL, BCP-ALL), 6 patients were 
pro-/pre-T, cortical or mature T-ALL (T-lineage ALL, 
T-ALL). Heterogeneous CD34 expression and suffi-
cient quantity of leukemic cells were the main criteria 
for choosing samples. ALL population was considered 
as heterogeneous when quantity of CD34 positive cells 
was between 10–90%.
This investigation was approved by the local Insti-
tutional Ethic Committee. Characteristics of patients 
are listed in Table 1.
Cell preparation. Leukemic cells of all used 
samples were isolated from bone marrow by gradi-
ent density centrifugation. Information about pattern 
of antigens expression was obtained from standard 
three-color immunophenotyping procedure.
Cell sorting. Leukemic cells were separated into 
CD34+ and CD34− fractions after CD34 PE labeling 
(Becton Dickinson, San Jose, CA, USA). Additional 
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labeling and gating according to CD45 FITC fluores-
cence were used to exclude normal cells contamina-
tion. Dead cells were excluded using forward and side 
scatter gating. The purity of sorted subpopulations was 
always more than 98%. Gating strategy was performed 
as described previously [15]. Leukemic cells sorting 
were carried out using FACSVantage SE (BD).
Real-Time PCR. Total RNA from sorted cells was 
extracted using Gen Elute Mammalian Total RNA 
Miniprep Kit (Sigma-Aldrich, St Louis, MO, USA). 
According to manufacturer’s protocol after first step 
(cell lysing) samples were stored at -70 °C. When 
needed, samples were thawed and RNA was extracted. 
Quantity and quality of obtained total RNA were de-
fined by spectrophotometry using Gene Quant RNA/
DNA Calculator (GE Healthcare). Reaction of reverse 
transcription was carried out immediately after RNA 
extraction using Advantage RT-for-PCR Kit (BD) ac-
cording to the manufacturer’s protocol.
cDNA from one extraction from IM-9 cell line 
was used as a standard and a calibrator for analy-
zing BCL-2, MDR1, LRP and BCRP gene expression 
in leukemic bone marrow blasts where all these genes 
expressed at levels comparable with those in the cell 
line. Normal gene GUS was used as a loading control 
gene [16].
We evaluated expression levels of experimental 
genes using real-time PCR (iCycler, BioRad). For 
calculating relative expression levels standard curves 
method was used. Each standard curve was gener-
ated according to four points of 10-fold dilutions 
of cDNA obtained from IM-9 cell line. Amplifications 
were carried out in a total volume of 25 μl containing 
cDNA, Platinum Quantitative PCR SuperMix-UDG 
(Invitrogene, Carlsbad, CA, USA, final concentration 
of MgCl2 was raised to 4mM), 300nM of forward and 
reverse primer, and 200nM of TaqMan probe. The 
following primers were used (5' to 3'): BCL-2 forward 
primer: TTG GCC CCC GTT GCT T, reverse primer: CGG 
TTG TCG TAC CCC GTT CTC, TaqMan probe: FAM AGC 
GTG CGC CAT CCT TCC CAG BHQ1; MDR1 forward 
primer: AGG AAG ACA TGA CCA GGT ATG C, reverse 
primer: CCA ACA TCG TGC ACA TCA AAC, TaqMan 
probe: FAM CCT GGC AGC TGG AAG ACA AAT ACA 
CAA BHQ1; LRP forward primer: CAG CTG GCC ATC 
GAG ATC A, reverse primer: TCC AGT CTC TGA GCC 
TCA TGC, TaqMan probe: FAM CAA CTC CCA GGA AGC 
GGC GGC BHQ1; BCRP forward primer: TGG CTG TCA 
TGG CTT CAG TA, reverse primer: GCC ACG TGA TTC 
TTC CAC AA, TaqMan probe: FAM AGC AGG GCA TCG 
AGC TCT CAC CCT G BHQ1.
Quantitative analysis of TEL-AML1 fusion gene 
expression in CD34+ and CD34- leukemic fractions 
was estimated with DNA-standards (Ipsogen, France) 
according to protocol of Gabert J. et al. [17] and nor-
malized to GUS expression [16].
Statistical analysis. Student’s test for paired 
samples was applied to determine significance of dif-
ferences between CD34+ and CD34- populations.
RESULTS
Bone marrow leukemic samples with heteroge-
neous expression of CD34 were separated into CD34+ 
and CD34− fractions by fluorescent activated cell 
sorting. Characteristics of patients included in this 
investigation are listed in Table1. Median values 
of CD34 positive leukemic cells for all selected patients 
was 50 % (from 14 to 80 %).
Table 1. Patient Characteristics
Patient 
№ Age ALL
CD34, 
% Heterogeneous markers
Fusion 
gene
1 2 BCP 70 CD45, CD13 Negative
2 <1 BCP 48 CD15 MLL-AF1p
3 5 BCP 58 CD5, CD117 Negative
4 8 BCP 50 CD20, CD33 Negative
5 16 BCP 22 CD33, CD11b Negative
6 2 BCP 33 CD45, CD10, CD19 TEL-AML1
7 2 BCP 34 CD45, CD20, CD15 TEL-AML1
8 6 BCP 59 DR, CD20, CD13, CD10, CD15 TEL-AML1
9 15 ВCP, relapse 46 DR Negative
10 3 BCP 70 CD20 TEL-AML1
11 15 BCP 46 DR, CD20,CD15 MLL-AF4
12 15 Т, relapse 80 CD13, CD11b Negative
13 15 Т 14 CD8, CD13, TdT SIL-TAL
14 13 Т 58 CD1a Negative
15 16 Т 67 CD4 Negative
16 14 Т 54 CD8, CD3, CD13, CD10, 
CD117, CD1a, TdT
Negative
17 10 Т 47 CD4, CD3, CD117, CD33, 
CD11b, TdT,
Negative
Previously we described apoptosis and prolifera-
tions differences in small groups of childhood ALL and 
AML samples [15]. Here expression levels of BCL-2, 
MDR1, LRP and BCRP genes were analyzed in CD34+/
CD34− subpopulations of childhood ALL. Differences 
in expression level of genes between studied subpopu-
lations in ≥two-fold we considered as significant when 
differences <two-fold were accounted as insignificant.
In general, in BCP-ALL group we found no evident 
trend to higher expression levels of any studied genes 
in CD34+ or CD34− fractions. In particular, BCL-2 gene 
expression levels to be higher in CD34+ cells vs CD34− 
cells only in 1 out of 11 samples (patient 1). Whereas 
in 2 out of 11 samples (patients 7, 8) expression lev-
els of BCL-2 were higher in CD34− cells, and in eight 
samples (73%) we found expression levels of this 
gene in CD34+ and CD34− subpopulations to be not 
significantly different (Fig. 1, a).
Higher expression levels of MDR1 gene in CD34+ 
vs CD34− cells was registered in 3 out of 11 samples 
(patients 3, 4, 6). However, in 4 out of 11 samples 
we registered lower expression level of MDR1 in CD34+ 
fraction. In four samples (36%) expression levels 
of MDR1 gene did not exceed two-fold difference 
(Fig. 1, B).
BCRP expression levels in CD34+ cells was higher 
in 1 out of 11 samples (patient 1); in 2 out of 11 samples 
(patient 2, 3) its expression in CD34+ subpopula-
tion was lower; and eight samples (73%) we found 
no difference (figure 1C). For all BCP-ALL patients 
expression levels of LRP gene did not exceed two-fold 
difference between CD34+ and CD34− subpopulations 
(figure 1D).
In T-ALL group differences in genes expression 
between CD34+ and CD34− subpopulations are rep-
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resented in Fig. 2. Antiapoptotic gene BCL-2 in 1 out 
of 6 samples (patient 17) had >two-fold higher ex-
pression in CD34− than CD34+ fraction while in other 
five samples we found negligible difference between 
fractions (figure 2a).
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Fig. 1. Expression levels of BCL-2 (a), MDR1 (b), BCRP (c) and 
LRP (d) genes in CD34+ and CD34- leukemic subpopulations 
in BCP-ALL
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Fig. 2. Expression levels of BCL-2 (a), MDR1 (b), BCRP (c) and 
LRP (d) genes in CD34+ and CD34- leukemic subpopulations 
in T-ALL
Expression levels of MDR1 gene in samples 
from T-ALL group were significantly higher compar-
ing to BCP-ALL group. For T-ALL samples median 
values of MDR1 expression for CD34+ and CD34− 
were 60.4 (range, 13.2–2384.0) and 117.2 (range, 
6.3–967.2) arbitrary units respectively, while it were 
2.7 (range, 0.16–15.3) and 3.6(range, 0.06–26.4) for 
CD34+ and CD34− subpopulations for BCP-ALL cases.
In 3 out of 6 samples (patients 12, 13, 15) MDR1 gene 
was expressed at higher levels in CD34+ cells than 
in CD34− cells and in 2 samples (patients 14, 16) it was 
expressed at lower levels in CD34+ cells; one sample 
had no two-fold difference.
Interestingly, for all T-ALL cases LRP gene was 
expressed in higher level in CD34− leukemic fractions 
than CD34+ ones. For patients 13, 14 and 16 differenc-
es in LRP expression levels between CD34− vs CD34+ 
were 2.7, 3.9 and 2.3 fold respectively. BCRP gene 
levels were higher in CD34− cells than CD34+ cells 
in 5 out of 6 samples, for three of them differences 
between CD34+ vs CD34− cells were >two-fold.
Then we supposed that genetic alterations in leu-
kemic cells could lead to a specific pattern of expres-
sion of investigated genes in CD34+ vs CD34− leuke-
mic fractions. TEL-AML1 fusion gene was detected 
in four leukemic samples. It was found out that for all 
four samples CD34+ leukemic fractions had higher 
level of TEL-AML1 expression, however parameters 
of genes expression were revealed in a variable extent 
(from no difference to > two fold difference) in CD34+/ 
CD34− leukemic subpopulations.
DISCUSSION
Currently it is evident that tumor tissues are com-
posed of heterogeneous combinations of cells with 
different phenotypic characteristics, proliferation 
potentials, self-renewal ability, etc. [18]. In this work 
we made an attempt to investigate biologic proper-
ties of CD34− and CD34+ leukemic cells with respect 
to a more “resistant phenotype” and a better chance 
of surviving during chemotherapy.
Apoptosis is an important mechanism that regu-
lates survival of leukemic cells. It was described that 
an intact apoptosis signaling was important for effi-
cient induction and maintenance of remission in child-
hood precursor B-cell ALL [19]; a relapse in childhood 
ALL was associated with decreased BAX/BCL-2 ratio 
and loss of spontaneous caspase-3 processing in vivo 
[20]. BCL-2 protein plays a critical role in inhibiting 
anticancer drug-induced apoptosis, constitutive over-
expression of BCL-2 is one of mechanisms of drug 
resistance in cancer [21]. Previously we described 
a decreased ability to apoptosis of CD34+ leukemic 
cells than CD34− fraction [15]. Such difference in apop-
tosis levels between subpopulations can be a result 
of different expression of BCL-2 gene. However, here 
our data did not reveal any considerable difference 
in BCL-2 gene expression between CD34+ vs CD34− 
fractions for BCP-ALL and for T-ALL.
Multidrug resistance phenotype is usually associ-
ated with efflux of anticancer agents from cells leading 
to a decreased drug accumulation. The role of MDR1, 
BCRP, LRP genes / proteins in drug resistance in leu-
kemia has been studied for years, however, the prog-
nostic role of these proteins in childhood ALL remains 
controversial [22–25].
Earlier, associations between expression of drug 
resistance associated genes/proteins, antiapop-
totic BCL-2 and CD34 expression were frequently 
described for AML patients [26–29]. However, these 
correlations were found rarely in ALL samples [23, 
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30–31]. Our results demonstrated that in the majority 
of B-lineage ALL cases CD34+/CD34− leukemic frac-
tions did not differ in expression of BCRP and LRP 
genes. On the other hand, for all analyzed T-lineage 
ALL samples CD34- leukemic fractions had increased 
level of BCRP (from 1.2 to 8.1 fold) and LRP (from 
1.2 to 3.9 fold) genes in comparison with CD34+. 
In the majority of patients with BCP- (7/11) and T-ALL 
(5/6) expression of MDR1 gene had >two-fold differ-
ence between subpopulations, however increased 
MDR1 gene expression was detected in CD34+ as well 
as in CD34− subpopulations. However recently it was 
described that expression of CD34 was associated 
with elevated MDR1 and MRP1 mRNA expression 
levels, but not LRP in pediatric T-ALL [32].
Investigations of drug resistance properties of sub-
populations became especially interesting in the light 
of new data that in childhood ALL blasts at all stages 
of immunophenotypic maturation have stem cell 
properties (ability to engraft and reconstitute leukemia 
in NOD/SCID mice) [33]. Normal hematopoietic and 
leukemic stem cells possess several characteristics 
that protect them from potential insults through the 
expression of ATP-associated transporters [34–35]. 
Therefore, we summarized all data comparing genes 
expression levels in CD34+ vs CD34− leukemic fractions 
obtained from children with BCP-ALL and T-ALL. Con-
ditionally we admit that if leukemic subpopulation 
(CD34+ or CD34−) had > two fold higher level at least 
of one of analyzed genes it means that this subpopu-
lation possess “resistant” properties. Thus, we sepa-
rated all analyzed cases into groups with “resistant” 
CD34+ cells, “resistant” CD34− cells, a group of cases 
with both subpopulations showed signs of a “resistant” 
phenotype and a group that showed no difference 
between two subpopulations (Table 2).
Table 2. Comparison of “resistant” properties CD34+ vs CD34− leukemic 
subpopulations 
BCP-ALL
n=11
T-lineage ALL
n=6
Only CD34+ subpopulation had resis-
tant properties
Patients 1, 4, 6 Patient 15
Only CD34− subpopulation had resis-
tant properties
Patients 2, 7, 8, 
9, 10, 11
Patients 14, 
16, 17
CD34+ and CD34− subpopulations had 
resistant properties
Patient 3 Patients 12, 13
No difference between CD34+ and 
CD34− subpopulations
Patient 5 0
According to our assumption, it was found that 
both studied subpopulations showed indications 
of a resistant phenotype. Among of all analyzed cases 
only one sample (5.9%) revealed no difference in re-
sistance associated features between cells with high 
and low CD34 expression. In 3 out of 17 cases (17.6%) 
both subpopulations displayed signs of a “resistant” 
phenotype. Surprisingly, only in 4 out of 17 ALL cases 
(23,5%) CD34+ cells had more pronounced resistance 
properties. Finally, in 9 out of 17 cases (52,9 %) CD34− 
subpopulation had properties of a resistant phenotype.
In conclusion, it was not found the unique pat-
tern of resistance related genes expression in CD34+ 
vs CD34− subpopulations however, in majority of stud-
ied pediatric ALL cases with CD34 heterogeneous ex-
pression one of subpopulations (positive or negative) 
could have an advantage for survival through elevated 
expression of drug resistance related genes. Further 
investigation is required to elucidate reasons and pat-
terns of such distinctions between subpopulations.
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